Avalo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Checking your notes…
(b) Director and Officer Trading Plans and Arrangements
During the three months ended December 31, 2025, the following directors and officers had adopted contracts, instructions or written plans for the purchase or sale of our securities as follow:
| Name and Title | Type of Trading Arrangement | Action Taken (Date of Action) | Duration or End Date | Aggregate Numbers of Securities to be Sold(1) | Description of Trading Arrangement |
|---|---|---|---|---|---|
| Mitchell Chan, Director | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption (November 19, 2025) | November 30, 2026 | 42,833(2) | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Mittie Doyle, Chief Medical Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption (November 13, 2025) | October 31, 2026 | 186,999 | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Jennifer Riley, Chief Strategy Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption (November 12, 2025) | November 30, 2026 | 12,000 | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Christopher Sullivan, Chief Financial Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption (November 12, 2025) | November 30, 2026 | 138,115(3) | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Paul Varki, Chief Legal Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption (November 12, 2025) | June 30, 2026 | 92,771 | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| (1) | Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the trading plans. |
| (2) | These shares reflect the aggregate maximum of shares underlying vested stock options and RSUs, including 3,166 RSUs that are expected to vest during the term of the trading plan. |
| (3) | These shares reflect the aggregate maximum of shares underlying vested stock options and RSUs, including 24,200 RSUs that are expected to vest during the term of the trading plan prior to expected share withholding or sell-to-cover to satisfy tax withholding obligations associated with the expected RSU vest. |
Other than as disclosed above, none of our directors or officers adopted, modified orterminated any Rule 10b5-1(c) trading arrangements or any non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended December 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.